News

Under the settlement and license agreement, Horizon has granted Perrigo the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under

Akynzeo is the first approved fixed dose combination oral agent that targets two critical signalling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron,

The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox

"For the first time, we have looked at the Scale clinical trial programme to explore to what degree the benefits of liraglutide 3 mg could be assigned to

The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for supporting the

Under the public-private partnership (PPP), research scientists from both parties will work together in an HIV Cure center, which will be located at UNC. The two entities will

As part of the deal, Thermo Fisher will further offer Horizon’s X-MAN haploid cell line generation service to its worldwide customer base with the exception of Japan. Horizon’s

Latuda is an atypical antipsychotic developed by Sumitomo, while it is characterized by a chemical structure and an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors

The proposed transaction also includes BASF’s production sites in Minden, Germany, Evionnaz, Switzerland, and Saint-Vulbas, France. About 850 positions globally are in the scope of the transaction and